[HTML][HTML] First-generation oral antivirals against SARS-CoV-2
Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19
J Hammond, RJ Fountaine, C Yunis… - … England Journal of …, 2024 - Mass Medical Soc
Background Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …
Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial
MG Johnson, A Puenpatom, PA Moncada… - Annals of internal …, 2022 - acpjournals.org
Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction
in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk …
in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk …
Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults
Y Caraco, GE Crofoot, PA Moncada… - NEJM …, 2022 - evidence.nejm.org
Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …
Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records
Objective To estimate the effectiveness of nirmatrelvir, compared with no treatment, in
reducing admission to hospital or death at 30 days in people infected with the SARS-CoV-2 …
reducing admission to hospital or death at 30 days in people infected with the SARS-CoV-2 …
The role of antiviral treatment in the COVID-19 pandemic
TK Burki - The Lancet Respiratory Medicine, 2022 - thelancet.com
On Dec 22, 2021, the US Food and Drug Administration (FDA) issued an emergency use
authorisation for Pfizer's COVID-19 antiviral, Paxlovid. Trial results released by the …
authorisation for Pfizer's COVID-19 antiviral, Paxlovid. Trial results released by the …
Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month …
KL Bajema, K Berry, E Streja, N Rajeevan… - Annals of internal …, 2023 - acpjournals.org
Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
Background We examined the safety and efficacy of a treatment protocol containing
Favipiravir for the treatment of SARS-CoV-2. Methods We did a multicenter randomized …
Favipiravir for the treatment of SARS-CoV-2. Methods We did a multicenter randomized …
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach
R Dal-Ré, SL Becker, E Bottieau… - The Lancet Infectious …, 2022 - thelancet.com
The first two oral antivirals, molnupiravir and nirmatrelvir–ritonavir, are now becoming
available in many countries. These medicines will be indicated to treat mild-to-moderate …
available in many countries. These medicines will be indicated to treat mild-to-moderate …